Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
This study is currently recruiting participants.
Verified May 2012 by Amylin Pharmaceuticals, LLC.
Study NCT01144338
Information provided by Amylin Pharmaceuticals, LLC.
First Received on June 10, 2010.
Last Updated on February 7, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study: